EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Use of beta-blockers in patients with ductal carcinoma in situ and risk of invasive breast cancer recurrence: a Swedish retrospective cohort study

Carina Strell, Daniel Robert Smith, Antonis Valachis, Hellén Woldeyesus, Charlotta Wadsten, Patrick Micke, Irma Fredriksson, Aglaia Schiza

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07358-y ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Carina Strell und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Genetics, and Pathology, Uppsala University, Dag Hammarskjölds Väg 20, 751 85, Uppsala, Sweden. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uppsala University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Retrospective observational studies suggest a potential role of beta-blockers as a protective strategy against progression and metastasis in invasive breast cancer. In this context, we investigated the impact of beta-blocker exposure on risk for progression to invasive breast cancer after diagnosis of ductal cancer in situ (DCIS).

Methods

The retrospective study population included 2535 women diagnosed with pure DCIS between 2006 and2012 in three healthcare regions in SwedenExposure to beta-blocker was quantified using a time-varying percentage of days with medication available. The absolute risk was quantified using cumulative incidence functions and cox models were applied to quantify the association between beta-blocker exposure and time from DCIS diagnosis to invasive breast cancer, accounting for delayed effects, competing risks and pre-specified confounders.

Results

The median follow-up was 8.7 years. One third of the patients in our cohort were exposed to beta-blockers post DCIS diagnosis. During the study period, 48 patients experienced an invasive recurrence, giving a cumulative incidence of invasive breast cancer progression of 1.8% at five years. The cumulative exposure to beta-blocker was associated with a reduced risk in a dose-dependent manner, though the effect was not statistically significant.

Conclusion

Our observational study is suggestive of a protective effect of beta-blockers against invasive breast cancer after primary DCIS diagnosis. These results provide rationales for experimental and clinical follow-up studies in carefully selected DCIS groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-AntagonistsBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingNeoplasm Recurrence, LocalHumansFemaleSwedenMiddle AgedRetrospective StudiesAgedAdultIncidenceDisease ProgressionFollow-Up StudiesNeoplasm InvasivenessRisk Factors

Stichwörter der Autor:innen

Beta-blockersBreast cancer recurrenceDCIS

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Department of Immunology, Genetics, and Pathology, Uppsala University, Dag Hammarskjölds Väg 20, 751 85, Uppsala, Sweden.
  • Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway.
  • Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden.
  • Department of Oncology, Faculty of Medicine and Health, Örebro University Hospital, Örebro University, Örebro, Sweden.
  • Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
  • Department of Surgical and Perioperative Sciences/Surgery, Umeå University, Umeå, Sweden.

Förderung

  • Uppsala University

Zitieren

APA

Strell, C., Smith, D. R., Valachis, A., Woldeyesus, H., Wadsten, C., Micke, P., Fredriksson, I., & Schiza, A. (2024). Use of beta-blockers in patients with ductal carcinoma in situ and risk of invasive breast cancer recurrence: a Swedish retrospective cohort study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07358-y

Vancouver

Strell C, Smith DR, Valachis A, Woldeyesus H, Wadsten C, Micke P, et al. Use of beta-blockers in patients with ductal carcinoma in situ and risk of invasive breast cancer recurrence: a Swedish retrospective cohort study. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07358-y

BibTeX
@article{Strell2024,
  author = {Strell, Carina and Smith, Daniel Robert and Valachis, Antonis and Woldeyesus, Hellén and Wadsten, Charlotta and Micke, Patrick and Fredriksson, Irma and Schiza, Aglaia},
  title = {Use of beta-blockers in patients with ductal carcinoma in situ and risk of invasive breast cancer recurrence: a Swedish retrospective cohort study},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07358-y}
}
Kostenlos starten →